Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Meguho Watanabe"'
Autor:
Meguho Watanabe, Masaki Kobayashi, Jiro Ogura, Natsuko Takahashi, Hiroaki Yamaguchi, Ken Iseki
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 17, Iss 1 (2014)
Purpose. Patients with type 2 diabetes are generally treated with various pharmacological compounds and are exposed to a high risk of drug-drug interactions. However, alterations of pharmacokinetics in a type 2 diabetes model have been obscure. The p
Externí odkaz:
https://doaj.org/article/feb9dadb940e47e7b8b505f47a515008
Autor:
Sho Otake, Shotaro Sasaki, Jiro Ogura, Ayako Furugen, Natsuko Takahashi, Katsuya Narumi, Ken Iseki, Hiroaki Yamaguchi, Masaki Kobayashi, Meguho Watanabe, Yurika Kikutani
Publikováno v:
Biologicalpharmaceutical bulletin. 36(9)
Protein kinase C (PKC) modulators are very attractive therapeutic targets in cancer. Since most cancer cells display increased glycolysis, elucidations of the effects of PKC activation on glycolysis is necessary for the development of effective medic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9a79afff903c29f6d7cfe8472d3a9e3
https://pubmed.ncbi.nlm.nih.gov/23995654
https://pubmed.ncbi.nlm.nih.gov/23995654
Autor:
Ken Iseki, Ayako Furugen, Masaki Kobayashi, Meguho Watanabe, Katsuya Narumi, Shirou Itagaki, Sho Otake
Publikováno v:
Life sciences. 88(3-4)
Aims The aim of this study was to determine the effect of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), an AMP-activated protein kinase (AMPK) activator, on monocarboxylate transporter 4 (MCT4) expression in rat skeletal muscle and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4461b01041033c91f056d24bfc9a6f5a
https://pubmed.ncbi.nlm.nih.gov/21070787
https://pubmed.ncbi.nlm.nih.gov/21070787
Autor:
Natsuko Takahashi, Hiroaki Yamaguchi, Meguho Watanabe, Masaki Kobayashi, Ken Iseki, Jiro Ogura
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 17, Iss 1 (2014)
Purpose. Patients with type 2 diabetes are generally treated with various pharmacological compounds and are exposed to a high risk of drug-drug interactions. However, alterations of pharmacokinetics in a type 2 diabetes model have been obscure. The p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4da94c7c7a49690790bedc13297927db
https://doi.org/10.18433/j3mc70
https://doi.org/10.18433/j3mc70